Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease.
Carl P WaltherWolfgang C WinkelmayerPeter A RichardsonSalim S ViraniSankar D NavaneethanPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2021)
In a cohort of predominantly male veterans with CKD Stages 3 and 4, ACEI/ARB discontinuation was independently associated with an increased risk of subsequent death and ESKD. This may be due to the severity of illness factors that drive the decision to discontinue therapy. Further investigations to determine the causes of discontinuations and to provide an evidence base for discontinuation decisions are needed.